Lenacapavir (Sunlenca) vs Lenacapavir (Yeztugo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV capsid · full HIV pipeline
Lenacapavir (Sunlenca)
Marketed by Gilead Sciences
NCT04143594 · Phase 2 · completed
The trial randomized 183 participants to lenacapavir-containing regimens or the active comparator B/F/TAF, but treatment was not blinded. The primary HIV-1 RNA suppression endpoint was a clinically relevant measure, yet all lenacapavir-versus-comparator comparisons were non-significant, so the results provide real but limited evidence for lenacapavir.
Next expected readout: March 2027 · NCT06749054 (registry estimate)
Reported efficacy
Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Cohort 1A: Lenacapavir 87.5 percentage of participants | Cohort 1B: Placebo to Lenacapavir 16.7 percentage of participants (met)
Result source: NCT04150068
Lenacapavir (Yeztugo)
Marketed by Gilead Sciences
NCT04994509 · Phase 3 · active, not recruiting
This is a very large randomized, double-blind trial with active-control arms and a hard primary endpoint, HIV-1 infection. Lenacapavir's HIV incidence was far below the background rate and met the prespecified superiority tests. The primary comparison is against a background rate estimated from screened participants, not directly against the control arms.
Next expected readout: March 2027 · NCT07210125 (registry estimate)
Reported efficacy
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY) (Incidence Phase Screening Visit (Day 1)); Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set) (Up to 149 weeks): HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025). (met)
Result source: NCT04925752
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Lenacapavir (Sunlenca) | Lenacapavir (Yeztugo) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 90.4% vs 92%vs B/F/TAFNCT0414359411 other results
| —Trial running · NCT04925752 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT06532656 | —Trial running · NCT04925752 |
| CD4 count, change (week 48) | 275 vs 248vs B/F/TAFNCT0414359411 other results
| —Trial running · NCT04925752 |
HIV-1 RNA below 50 copies/mL (week 48)
- Lenacapavir (Sunlenca)
- 90.4% vs 92%vs B/F/TAFNCT04143594
11 other results
- 84.9% vs 92% NCT04143594
- 84.6% vs 92% NCT04143594
- 86.5% vs 92% NCT04143594
- 75.5% vs 92% NCT04143594
- 86.5% vs 92% NCT04143594
- 90.4% vs 96% NCT04143594
- 88.7% vs 96% NCT04143594
- 88.5% vs 96% NCT04143594
- 94.2% vs 100% NCT04143594
- 92.5% vs 100% NCT04143594
- 94.2% vs 100% NCT04143594
- Lenacapavir (Yeztugo)
- —Trial running · NCT04925752
HIV-1 RNA 50 copies/mL or more (week 48)
- Lenacapavir (Sunlenca)
- —Trial running · NCT06532656
- Lenacapavir (Yeztugo)
- —Trial running · NCT04925752
CD4 count, change (week 48)
- Lenacapavir (Sunlenca)
- 275 vs 248vs B/F/TAFNCT04143594
11 other results
- 262 vs 248 NCT04143594
- 245 vs 248 NCT04143594
- 204 vs 193 NCT04143594
- 213 vs 193 NCT04143594
- 220 vs 193 NCT04143594
- 195 vs 232 NCT04143594
- 220 vs 232 NCT04143594
- 211 vs 232 NCT04143594
- 172 vs 163 NCT04143594
- 158 vs 163 NCT04143594
- 206 vs 163 NCT04143594
- Lenacapavir (Yeztugo)
- —Trial running · NCT04925752
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lenacapavir (Sunlenca): 4 of 4 rows · Lenacapavir (Yeztugo): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lenacapavir (Sunlenca) | Lenacapavir (Yeztugo) |
|---|---|---|
| Dropout rate | 21.2%Group 1: SC LEN+(F/TAF→ TAF)a NCT04143594 · Phase 2 · combination show 7 more results34%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · combination 30.8%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · combination 16.7%750 mg NCT03739866 · Phase 1 · registry result, not featured evidence 16.7%450 mg NCT03739866 · Phase 1 · registry result, not featured evidence 14.3%150 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%50 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%20 mg NCT03739866 · Phase 1 · registry result, not featured evidence | 11.5% NCT04994509 · Phase 3 · combination · HIV · phase 3 show 1 more result94.4% NCT04925752 · Phase 3 · combination · HIV · phase 3 |
| Discontinued due to AEs | 1.9%Group 1: SC LEN+(F/TAF→ TAF)a NCT04143594 · Phase 2 · combination show 7 more results0%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · combination 0%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · combination —750 mg NCT03739866 · Phase 1 · registry result, not featured evidence —450 mg NCT03739866 · Phase 1 · registry result, not featured evidence —150 mg NCT03739866 · Phase 1 · registry result, not featured evidence —50 mg NCT03739866 · Phase 1 · registry result, not featured evidence —20 mg NCT03739866 · Phase 1 · registry result, not featured evidence | 0.1% NCT04994509 · Phase 3 · combination · HIV · phase 3 show 1 more result0.2% NCT04925752 · Phase 3 · combination · HIV · phase 3 |
| Serious AEs | 7.7%Group 1: SC LEN+(F/TAF→ TAF)a NCT04143594 · Phase 2 · combination show 7 more results7.5%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · combination 13.5%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · combination 0%750 mg NCT03739866 · Phase 1 · registry result, not featured evidence 16.7%450 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%150 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%50 mg NCT03739866 · Phase 1 · registry result, not featured evidence 0%20 mg NCT03739866 · Phase 1 · registry result, not featured evidence | 3.8% NCT04994509 · Phase 3 · combination · HIV · phase 3 show 1 more result3.3% NCT04925752 · Phase 3 · combination · HIV · phase 3 |
| Most frequent reported AEs | a injection site erythema 48.1% injection site swelling 32.7% injection site pain 28.8% NCT04143594 · Phase 2 · combination show 7 more resultsinjection site erythema 34% injection site swelling 34% injection site pain 26.4% NCT04143594 · Phase 2 · combination 750 mg injection site pain 80% (placebo 30%) injection site erythema 40% (placebo 10%) injection site nodule 40% (placebo 0%) NCT03739866 · Phase 1 · registry result, not featured evidence 450 mg injection site pain 66.7% (placebo 30%) upper respiratory tract infection 66.7% (placebo 0%) injection site erythema 33.3% (placebo 10%) NCT03739866 · Phase 1 · registry result, not featured evidence 150 mg injection site erythema 66.7% (placebo 10%) injection site pain 66.7% (placebo 30%) injection site induration 50% (placebo 10%) NCT03739866 · Phase 1 · registry result, not featured evidence 50 mg injection site pain 66.7% (placebo 30%) syphilis 33.3% (placebo 0%) acne 16.7% (placebo 0%) NCT03739866 · Phase 1 · registry result, not featured evidence 20 mg headache 33.3% (placebo 20%) anogenital dysplasia 16.7% (placebo 0%) conjunctivitis allergic 16.7% (placebo 0%) NCT03739866 · Phase 1 · registry result, not featured evidence | injection site nodule 66.1% injection site pain 34.2% genitourinary chlamydia infection 16.4% NCT04994509 · Phase 3 · combination · HIV · phase 3 show 1 more resultinjection site nodule 63.4% injection site pain 56.4% injection site erythema 17.3% NCT04925752 · Phase 3 · combination · HIV · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lenacapavir (Sunlenca)
show 16 more results
show 16 more results
show 11 more results
Lenacapavir (Yeztugo)
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lenacapavir (Sunlenca)'s landscape · Lenacapavir (Yeztugo)'s landscape